Cargando…

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials

SIMPLE SUMMARY: Renal cancer is within the top 10 most common malignancies worldwide, of which clear cell histology represents the most common subtype in this cancer. Within the past few years, immunotherapy has been approved as a first-line therapy for metastatic renal cell carcinoma. Immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Tony Zibo, Case, Katherine, Olsen, Timothy Anders, Brown, Jacqueline T., Carthon, Bradley C., Kucuk, Omer, Goldman, Jamie, Harris, Wayne, Bilen, Mehmet Asim, Nazha, Bassel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220801/ https://www.ncbi.nlm.nih.gov/pubmed/35740533 http://dx.doi.org/10.3390/cancers14122867

Ejemplares similares

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2021)

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
por: Martini, Dylan J., et al.
Publicado: (2022)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma
por: Nazha, Bassel, et al.
Publicado: (2022)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
por: Olsen, T. Anders, et al.
Publicado: (2021)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT
por: Bilen, Mehmet Asim, et al.
Publicado: (2022)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device
por: Chu, Chia-Heng, et al.
Publicado: (2021)

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
por: Carlisle, Jennifer Wilkinson, et al.
Publicado: (2022)

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
por: Bilen, Mehmet A., et al.
Publicado: (2021)

Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database
por: Janopaul-Naylor, James Robert, et al.
Publicado: (2020)

A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma
por: Sekar, Rishi R., et al.
Publicado: (2017)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Management of metastatic renal cell carcinoma: The complexity of choice
por: Brown, Jacqueline T., et al.
Publicado: (2019)

Editorial: Case reports in renal cell carcinoma
por: Zhuang, Tony Z., et al.
Publicado: (2023)

A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
por: Rhoades Smith, Katherine Emilie, et al.
Publicado: (2019)

Cardiomyopathy Classification: Ongoing Debate in the Genomics Era
por: McCartan, Charles, et al.
Publicado: (2012)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells
por: Boya, Mert, et al.
Publicado: (2022)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe
por: Malicki, Stanisław, et al.
Publicado: (2022)

Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix
por: Zong, Liju, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
por: Zarrabi, Kevin, et al.
Publicado: (2021)

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
por: Alhalabi, Omar, et al.
Publicado: (2023)

A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
por: Yu, Eun-mi, et al.
Publicado: (2021)

Red blood cell distribution width is worthwhile when interpreted with other inflammatory markers
por: Dogan, Mehmet, et al.
Publicado: (2015)

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
por: Martini, Dylan J., et al.
Publicado: (2021)

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
por: Guram, Kripa, et al.
Publicado: (2019)

Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
por: Stern, Peter L., et al.
Publicado: (2021)

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy
por: Parosanu, Andreea, et al.
Publicado: (2022)

A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
por: Palma dos Reis, Ana Filipa, et al.
Publicado: (2022)

Therapeutic Vaccines for Genitourinary Malignancies
por: Dutcher, Giselle M. A., et al.
Publicado: (2018)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Yoshida, Takashi, et al.
Publicado: (2021)

A Novel Ferroptosis-Related Pathway for Regulating Immune Checkpoints in Clear Cell Renal Cell Carcinoma
por: Gao, Su, et al.
Publicado: (2021)

Construction and Validation of a Novel Immune Checkpoint-Related Model in Clear Cell Renal Cell Carcinoma
por: Fan, ZhiXiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jkbnjcl80m54m1nimitgr979nr